First preclinical data of SAIL-66 for cancer immunotherapy

Nov. 9, 2023

Researchers from Chugai Pharmaceutical Co. Ltd. presented preclinical data of SAIL-66, a trispecific antibody targeting Claudin-6 (CLDN6), CD137 (4-1BB) and CD3, for cancer immunotherapy.

BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer

Today's news in brief

BioWorld

BioWorld briefs for April 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 11, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...